Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22924729 | 0.89 | FOLH1 (0.58) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| SCHEMBL1817886 | 0.88 | FOLH1 (0.66) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| SCHEMBL30395109 | 0.88 | FOLH1 (0.66) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| SCHEMBL371526 | 0.88 | FOLH1 (0.70) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| SCHEMBL27705284 | 0.87 | FOLH1 (0.56) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| SCHEMBL27705268 | 0.85 | FOLH1 (0.58) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| SCHEMBL1980273 | 0.85 | FOLH1 (0.61) | FOLH1CYP2D6CYP2C9HIF1AAKR1C3 | |
| SCHEMBL1296456 | 0.85 | FOLH1 (0.61) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| SCHEMBL1421808 | 0.84 | FOLH1 (0.66) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| SCHEMBL16559877 | 0.84 | FOLH1 (0.66) | FOLH1CYP2D6CYP2C9HIF1AANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939943-B | Benzimidazole compound, preparation method thereof and application of benzimidazole compound in preparation of iron death inhibitor | 中山大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-112939943-A | Benzimidazole compound, preparation method thereof and application of benzimidazole compound in preparation of iron death inhibitor | 中山大学 | 2021-06-11 | — | — | CN | disclosed |
| CN-102459227-A | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | disclosed |
| US-20110112299-A1 | TETRACYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2308880-A1 | TETRACYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| CN-100491323-C | Biaryloxymethylarenecarboxylic acids compound | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | CN | disclosed |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-04-23 | — | — | US | disclosed |
| EP-1912977-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | Merck Frosst Canada Ltd. (CA) | 2008-04-23 | — | — | EP | disclosed |
| CN-101068803-A | Biaryloxymethylarene carboxylic acid compounds | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| WO-2007014454-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK FROSST CANADA LTD. (CA) | 2007-02-08 | — | — | WO | disclosed |
| CN-1812956-A | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112299-A1 | TETRACYCLIC COMPOUND | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, LPXN | FOLH1 4412/4885ALDH1A1 3255/4885HPGD 2776/4885 |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | FOLH1 1903/4885ALDH1A1 3109/4885HPGD 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.